53
Participants
Start Date
February 29, 2012
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
Rituximab
intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
Glatiramer Acetate
20 mg injected subcutaneously daily
Placebo
Subjects will receive an intravenous (IV) infusion of 1000 mg of rituximab or placebo (normal saline) on study days 1 (baseline visit) and 15 according to the rituximab infusion protocol. On study day 28, all subjects will initiate standard GA therapy, 20 mg injected subcutaneously daily.
University of Colorado Hospital, Aurora
Rocky Mountain MS Research Group, LLC
OTHER
University of Colorado, Denver
OTHER